1. Outcomes of trabeculectomy with polyvinylpyrrolidone collagen versus mitomycin in primary open angle glaucoma. 36-month follow-up
- Author
-
M. Alvarez-Padilla, P. Tolosa-Tort, Jesus Jimenez-Roman, F. Gil-Carrasco, A. Castillejos-Chevez, and D. Alvarez-Ascencio
- Subjects
medicine.medical_specialty ,Univariate analysis ,genetic structures ,Open angle glaucoma ,business.industry ,medicine.medical_treatment ,Mitomycin C ,Glaucoma ,General Medicine ,medicine.disease ,eye diseases ,03 medical and health sciences ,0302 clinical medicine ,Ophthalmology ,030221 ophthalmology & optometry ,medicine ,Glaucoma surgery ,Trabeculectomy ,sense organs ,business ,Adverse effect ,030217 neurology & neurosurgery ,Month follow up - Abstract
Purpose Describe and compare the effects of intraoperative application of Polyvinylpyrrolidone Collagen (PVP) versus Mitomycin C (MMC) on the pattern of change in mean IOP reduction and mean number of medications over 36-months follow-up in patients with primary open angle glaucoma (POAG) undergoing trabeculectomy. Methods Prospective, randomized, comparative study. Twenty-six eyes of 26 patients with POAG and no previous incisional glaucoma surgery underwent trabeculectomy and were randomized to PVP or MMC and completed a 36-month follow-up. Main outcome measures were IOP and number of glaucoma medications. Multivariate longitudinal analysis was performed by fitting a linear trend model adjusting for baseline response for the IOP outcome and a log-linear regression model with within-subject associations for the number of hypotensive medications outcome. Sensitivity analysis was performed to assess lower and higher order polynomial trends over time in IOP. Results The univariate analysis revealed that the mean IOP reduction from baseline to 36 months was 7.62 mmHg (3.05,12.18) in the MMC group and 8.15 mmHg (−0.64,16.95) in the PVP group. Mean percentage IOP reduction from baseline was 37.09% (15.93,58.17) and 36.08% (5.16,67.20) in the PVP group. Mean change in number of medications from baseline to 36 months was −0.92 medications (−3.38, +1.54)) for the MMC group and −1 medication (−3.12, +1.12). Both groups had a statistically significant decline in mean IOP over the follow-up period (p Conclusions The use of PVP during trabeculectomy achieves and maintains a statistically significant IOP reduction from baseline to 36 months and decreases the number of glaucoma medications. Secondary outcome measures showed a lower incidence of adverse events in the PVP group.
- Published
- 2021